C. Ann Merrifield
CIK: 0001247224
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lyra Therapeutics, Inc.
Discretionary Trading P&L
Holdings
C. Ann Merrifield files insider reports with the SEC as Director of Lyra Therapeutics, Inc. (LYRA). Signal8 holds 1 reported Form 4/5 transaction by C. Ann Merrifield since Sep 2024. The most recent reported transaction is a grant / award (Form 4 code A) in LYRA, dated May 14, 2025.
About MERRIFIELD C ANN
MERRIFIELD C ANN (SEC CIK 0001247224) files insider reports with the SEC as Director of Lyra Therapeutics, Inc. (LYRA).
Signal8 holds 1 ownership filing by MERRIFIELD C ANN, a Form 4, filed on May 16, 2025. Those filings report 1 transaction, the latest on May 14, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on MERRIFIELD C ANN's filings is in WATERTOWN, MA.
Recent filings by MERRIFIELD C ANN
- May 14, 2025: Grant or award of LYRA derivative securities (Form 4, code A).
Other insiders filing for Lyra Therapeutics, Inc. (LYRA)
- Smith W Bradford, Director
- Palasis Maria, Principal Executive Officer
- Cavalier Jason, Principal Financial Officer
- PERCEPTIVE ADVISORS LLC, 10% Owner
- TOBIN JAMES R, Director
- snyderman nancy lynn MD, Director